Michael Lock

1.9k total citations · 2 hit papers
37 papers, 1.4k citations indexed

About

Michael Lock is a scholar working on Epidemiology, Psychiatry and Mental health and Endocrinology. According to data from OpenAlex, Michael Lock has authored 37 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Epidemiology, 12 papers in Psychiatry and Mental health and 11 papers in Endocrinology. Recurrent topics in Michael Lock's work include Epilepsy research and treatment (12 papers), Vibrio bacteria research studies (11 papers) and Influenza Virus Research Studies (9 papers). Michael Lock is often cited by papers focused on Epilepsy research and treatment (12 papers), Vibrio bacteria research studies (11 papers) and Influenza Virus Research Studies (9 papers). Michael Lock collaborates with scholars based in United States, Belgium and France. Michael Lock's co-authors include Marc Gurwith, Bradley S. Galer, Anupam Agarwal, Gail Farfel, Kelly G. Knupp, Arnold R. Gammaitoni, Lieven Lagae, Glenn Morrison, Joseph Sullivan and Berten Ceulemans and has published in prestigious journals such as The Lancet, The Science of The Total Environment and Neurology.

In The Last Decade

Michael Lock

37 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial

2019 249 citations Lieven Lagae, Joseph Sullivan et al. The Lancet profile →
Fenfluramine for Treatment-Resistant Seizures in Patients With Dravet Syndrome Receiving Stiripentol-Inclusive Regimens

2019 180 citations Rima Nabbout, Arun Mistry et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael Lock United States	17	628	417	306	286	241	37	1.4k
Nuno Sepúlveda Portugal	26	245 0.4×	166 0.4×	434 1.4×	60 0.2×	168 0.7×	83	2.0k
Pieter Neels Belgium	14	137 0.2×	115 0.3×	95 0.3×	72 0.3×	224 0.9×	36	627
Emmanouil Magiorkinis Greece	20	115 0.2×	38 0.1×	246 0.8×	53 0.2×	356 1.5×	62	1.5k
Toni Whistler United States	21	349 0.6×	17 0.0×	331 1.1×	58 0.2×	212 0.9×	62	1.4k
Richard M. Rothberg United States	21	59 0.1×	63 0.2×	313 1.0×	211 0.7×	140 0.6×	75	1.6k
Douglas B. Tang United States	24	34 0.1×	86 0.2×	154 0.5×	49 0.2×	422 1.8×	38	1.8k
Mary Warrell United Kingdom	26	101 0.2×	89 0.2×	271 0.9×	28 0.1×	797 3.3×	45	3.6k
Brett A. Lidbury Australia	23	317 0.5×	14 0.0×	174 0.6×	77 0.3×	710 2.9×	73	1.8k
Nicolas Tchitchek France	23	146 0.2×	10 0.0×	596 1.9×	80 0.3×	364 1.5×	74	1.8k
Julie Mack United States	15	20 0.0×	172 0.4×	140 0.5×	66 0.2×	89 0.4×	36	1.0k

Countries citing papers authored by Michael Lock

Since Specialization

Citations

This map shows the geographic impact of Michael Lock's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Lock with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Lock more than expected).

Fields of papers citing papers by Michael Lock

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Lock. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Lock. The network helps show where Michael Lock may publish in the future.

Co-authorship network of co-authors of Michael Lock

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Lock. A scholar is included among the top collaborators of Michael Lock based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Lock. Michael Lock is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Scheffer, Ingrid E., Rima Nabbout, Lieven Lagae, et al.. (2025). Long‐term safety and effectiveness of fenfluramine in children and adults with Dravet syndrome. Epilepsia. 66(6). 1919–1932. 1 indexed citations

Beaty, Shannon M., Nicos Karasavvas, Robert A. Kuschner, et al.. (2023). A Phase 1 Two-Arm, Randomized, Double-Blind, Active-Controlled Study of Live, Oral Plasmid-Derived Adenovirus Type 4 and Type 7 Vaccines in Seronegative Adults. Vaccines. 11(6). 1091–1091. 1 indexed citations

Sullivan, Joseph, Lieven Lagae, J. Helen Cross, et al.. (2023). Fenfluramine in the treatment of Dravet syndrome: Results of a third randomized, placebo‐controlled clinical trial. Epilepsia. 64(10). 2653–2666. 31 indexed citations

Knupp, Kelly G., Ingrid E. Scheffer, Berten Ceulemans, et al.. (2022). Interim Analysis of Long-Term Safety and Efficacy of FINTEPLA (fenfluramine) in Patients with Lennox-Gastaut Syndrome (S13.010). Neurology. 98(18_supplement). 2 indexed citations

Knupp, Kelly G., Ingrid E. Scheffer, Berten Ceulemans, et al.. (2022). Fenfluramine provides clinically meaningful reduction in frequency of drop seizures in patients with Lennox–Gastaut syndrome: Interim analysis of an open‐label extension study. Epilepsia. 64(1). 139–151. 36 indexed citations

Cross, J. Helen, Bradley S. Galer, António Gil‐Nagel, et al.. (2021). Impact of fenfluramine on the expected SUDEP mortality rates in patients with Dravet syndrome. Seizure. 93. 154–159. 61 indexed citations

Sullivan, Joseph, Stéphane Auvin, Milka Pringsheim, et al.. (2020). Long-Term (2-Year) Safety and Efficacy of Adjunctive ZX008 (Fenfluramine Hydrochloride Oral Solution) for Dravet Syndrome: Interim Results of an Ongoing Open-Label Extension Study (4684). Neurology. 94(15_supplement). 5 indexed citations

McCarty, James, et al.. (2019). Age-related immunogenicity and reactogenicity of live oral cholera vaccine CVD 103-HgR in a randomized, controlled clinical trial. Vaccine. 37(11). 1389–1397. 10 indexed citations

Lagae, Lieven, Joseph Sullivan, Kelly G. Knupp, et al.. (2019). Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial. The Lancet. 394(10216). 2243–2254. 249 indexed citations breakdown →

10.

Haney, Douglas J., Michael Lock, Marc Gurwith, et al.. (2018). Lipopolysaccharide-specific memory B cell responses to an attenuated live cholera vaccine are associated with protection against Vibrio cholerae infection. Vaccine. 36(20). 2768–2773. 20 indexed citations

11.

McCarty, James, et al.. (2018). Safety and immunogenicity of single-dose live oral cholera vaccine strain CVD 103-HgR in healthy adults age 18–45. Vaccine. 36(6). 833–840. 14 indexed citations

12.

Chen, Wilbur H., Mitchell B. Cohen, Beth D. Kirkpatrick, et al.. (2016). Single-dose Live Oral Cholera Vaccine CVD 103-HgR Protects Against Human Experimental Infection WithVibrio choleraeO1 El Tor. Clinical Infectious Diseases. 62(11). 1329–1335. 128 indexed citations

13.

Jain, Manish, Mukundan Attur, John A. Todd, et al.. (2014). Increased Plasma IL-17F Levels in Rheumatoid Arthritis Patients Are Responsive to Methotrexate, Anti-TNF, and T Cell Costimulatory Modulation. Inflammation. 38(1). 180–186. 26 indexed citations

14.

Gurwith, Marc, Michael Lock, Eve M. Taylor, et al.. (2013). Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 study. The Lancet Infectious Diseases. 13(3). 238–250. 122 indexed citations

15.

Chen, Wilbur H., Richard N. Greenberg, Marcela F. Pasetti, et al.. (2013). Safety and Immunogenicity of Single-Dose Live Oral Cholera Vaccine Strain CVD 103-HgR, Prepared from New Master and Working Cell Banks. Clinical and Vaccine Immunology. 21(1). 66–73. 40 indexed citations

16.

Jobes, David V., et al.. (2006). High Incidence of Unusual Cysteine Variants in gp120 Envelope Proteins from Early HIV Type 1 Infections from a Phase 3 Vaccine Efficacy Trial. AIDS Research and Human Retroviruses. 22(10). 1014–1021. 13 indexed citations

17.

Gorse, Geoffrey J., W Keitel, Harry Keyserling, et al.. (2006). Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: A randomized, double-blinded, controlled, multicenter trial. Vaccine. 24(33-34). 5950–5959. 83 indexed citations

18.

Empig, Cyril, Julie Kenner, Edward F. Bell, et al.. (2005). Highly attenuated smallpox vaccine protects rabbits and mice against pathogenic orthopoxvirus challenge. Vaccine. 24(17). 3686–3694. 46 indexed citations

19.

Tarter, Michael E., Michael Lock, & Roberta M. Ray. (1995). Conditional switching: a new variety of regression with many potential environmental applications.. Environmental Health Perspectives. 103(7-8). 748–755. 1 indexed citations

20.

Tarter, Michael E. & Michael Lock. (1993). Statistical applications of expanding computer capabilities : proceedings of the 25th Symposium on the Interface. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact